Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: Results of the UK NCRI R-CHOP-14 versus 21 trial

M Gleeson1, N Counsell2, D Cunningham1*, N Chadwick2, A Lawrie2, E Hawkes3,4, A McMillan5, K Ardershna6,7, A Jack8, P Smith2, P Mouncey2, C Pocock5, J Radford10, J Davies11, D Turner12, A Kruger13, P Johnson14, J Gambell2, D Linch6

1Department of Medicine, The Royal Marsden Hospital, London and Surrey, United Kingdom,
2Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, United Kingdom
3Department of Oncology and Clinical Haematology, Austin Health, Heidelberg, Melbourne, Australia,
4Department of Medical Oncology, Eastern Health, Melbourne Australia,
5Department of Haematology, Nottingham City Hospital, Nottingham, United Kingdom,
6Department of Haematology, University College London, London, United Kingdom,
7Department of Haematology, Mount Vernon Cancer Centre, Northwood, United Kingdom,
8HMDS, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom,
9Department of Haematology, East Kent Hospitals, Canterbury, United Kingdom,
10The University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom,
11Department of Haematology, Western General Hospital, Edinburgh, United Kingdom,
12Department of Haematology, Torbay Hospital, Torquay, United Kingdom,
13Department of Haematology, Royal Cornwall Hospital, Truro, United Kingdom,
14Cancer Research UK Centre, Southampton, United Kingdom

© The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.
Abstract:

Background: Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is associated with a dismal prognosis. Here we report an analysis of CNS relapse for patients treated within the UK NCRI phase III R-CHOP 14 versus 21 randomised trial.

Patients and Methods: The R-CHOP 14 versus 21 trial compared rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) administered 2- versus 3-weekly in previously untreated patients aged ≥18 years with bulky stage I-IV DLBCL (n=1,080). Details of CNS prophylaxis were retrospectively collected from participating sites. The incidence of and risk factors for CNS relapse including application of the CNS-IPI were evaluated.

Results: 177/984 patients (18.0%) received prophylaxis (intrathecal (IT) methotrexate (MTX) n=163, intravenous (IV) MTX n=2, prophylaxis type unknown n=11 and IT MTX and cytarabine n=1). At a median follow-up of 6.5 years, 21 cases of CNS relapse (isolated n=11, with systemic relapse n=10) were observed, with a cumulative incidence of 1.9%. For patients selected to receive prophylaxis the incidence was 2.8%. Relapses predominantly involved the brain parenchyma (81.0%) and isolated leptomeningeal involvement was rare (14.3%). Univariable analysis (UVA) demonstrated the following risk factors for CNS relapse: PS 2, elevated LDH, IPI, >1 extranodal site of disease and presence of a ‘high-risk’ extranodal site. Due to the low number of events no factor remained significant in multivariate analysis (MVA). Application of the CNS-IPI revealed a high-risk group (4-6 risk factors) with a 2 and 5-year incidence of CNS relapse of 5.2% and 6.8% respectively.
Conclusion: Despite very limited use of IV MTX as prophylaxis, the incidence of CNS relapse following R-CHOP was very low (1.9%) confirming the reduced incidence in the rituximab era. The CNS-IPI identified patients at highest risk for CNS recurrence.

Trial number: ISCRRTN 16017947 (R-CHOP14v21)

Key words

Diffuse large B-cell lymphoma, rituximab, central nervous system, relapse

Key message

We provide a detailed analysis of CNS relapse for patients with diffuse large B-cell lymphoma treated within the phase 3 UK NCRI R-CHOP14 v21 trial. Our data demonstrate a very low incidence of CNS relapse in a uniformly R-CHOP-treated trial population despite limited use of intravenous methotrexate as prophylaxis.
Introduction:

CNS relapse is a devastating complication of diffuse large B-cell lymphoma (DLBCL) associated with a median survival of 2-5 months.[1] The risk appears to be less in the rituximab era[2, 3] however the data is conflicting, with a decreased incidence in some [4–9] but not all reported series.[10–13]

Chemoprophylaxis frequently with IT or IV MTX, is a longstanding strategy aiming to reduce the risk of CNS recurrence in DLBCL; however there is a risk of associated toxicity and limited evidence of efficacy. As the reported incidence of CNS relapse in the rituximab era in the absence of prophylaxis is 5.4%[10] administration is currently limited to high-risk patients.

Several risk factors for CNS recurrence have been reported including involvement of various extranodal (EN) sites by lymphoma at baseline, involvement of >1 EN site of disease (alone or in combination raised lactate dehydrogenase (LDH) level), as well as a high-intermediate/high-risk International Prognostic Index (IPI) score, which are well-summarised by McMillan et al[2]. In addition several biomarkers including activated B-cell (ABC) subtype [14], dual expression of MYC and BCL-2 by immunohistochemistry (IHC) [14] or MYC or double-hit rearrangement [15] are associated with increased risk.

Recently the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) reported a 6-factor prognostic model, the CNS-IPI, incorporating the 5 IPI factors and presence or absence of kidney and/or adrenal gland involvement to determine the risk of CNS relapse for patients with aggressive B-cell lymphoma. This model stratified patients into 3 risk groups for CNS relapse at 2 years: low [0-1 factors, 0.6% (95% CI 0-1.2)]; intermediate [2-3 factors, 3.4 % (95% CI 2.2-4.4)] and high risk [4-6...
factors, 10.2% (95% CI 6.3-14.1)]; and was subsequently validated in an independent population-based cohort of R-CHOP-treated patients with DLBCL from the British Columbia Cancer Agency (BCCA). [16]

Here we report an analysis evaluating CNS relapse for patients enrolled within the prospective randomised UK NCRI R-CHOP-14 versus 21 trial, including an evaluation of the CNS-IPI within this cohort and data regarding delivery of prophylaxis.

Patients and Methods:

The phase III randomised R-CHOP 14 versus 21 trial compared R-CHOP administered 2-weekly versus 3-weekly in the first-line treatment of DLBCL. A total of 1,080 patients aged ≥18 years with previously untreated bulky stage I-IV DLBCL were enrolled at 119 centres across the UK between March 2005 and November 2008. We previously reported that the primary endpoint of superior overall survival (OS) with R-CHOP-14 compared to R-CHOP-21 was not met, and that R-CHOP-14 was not superior to R-CHOP-21 for progression-free survival (PFS), response rate or safety.[17] Patients with primary mediastinal B-cell lymphoma (PMBL) were not excluded from trial participation and we recently reported our outcomes for this subgroup of patients. [18]

In accordance with the study protocol administration of CNS prophylaxis (12.5mg IT MTX) with the first 3 cycles of treatment or according to local guidelines) was at the discretion of the local investigator, but recommended for patients with involvement of bone marrow, peripheral blood, nasal/paranasal sinuses, orbit and testis. Details of CNS prophylaxis were retrospectively collected from participating sites using case report forms (CRFs).

The study database was interrogated to identify all cases where the CNS was documented as a site of relapse at initial disease progression. To ensure that all cases were captured local investigators reporting progressive disease (PD) were also contacted to confirm if the CNS was a site of involvement. Where a case of CNS relapse was identified investigators were asked to confirm the site(s) involved.
The primary endpoint of this analysis was to determine the incidence of CNS relapse. PFS and OS were calculated from the date of registration, censored at the date last seen, and analysed using Kaplan-Meier (KM) method.

Univariable and multivariable Cox regression analyses were performed to investigate the risk factors for CNS relapse. The Chi-Squared Test or Fisher’s exact test were used to compare the demographics between the following groups: group 1 (disease-free, n=795), group 2 (systemic relapse, n=264) versus group 3 + 4 (CNS relapse (n=21: non-isolated n=10, isolated n=11).

The following parameters were assessed: sex, age (≤60 versus >60 years), WHO performance status (PS) (<2 versus 2), stage (I/II versus III/IV), bulky disease >10cm (present versus absent), B symptoms (present versus absent), elevated LDH (present versus absent), IPI (0,1,2,3,4,5), >1 extranodal site (present versus absent), presence of a ‘high-risk’ extranodal site (bone, bone marrow, breast, kidney, orbit, nasal/paranasal sinuses, epidural space, peripheral blood and testis) (present versus absent), trial arm (R-CHOP-14 versus R-CHOP-21), CNS prophylaxis (yes versus no), cell-of-origin (COO) by Hans[19] algorithm (germinal centre B-cell (GCB) versus non-GCB subtype), BCL 2 translocation by fluorescence in-situ hybridization (FISH) (present versus absent), BCL 6 rearrangement by FISH (present versus absent), MYC rearrangement by FISH (present versus absent), double-hit by FISH (present versus absent), MIB1 (<90 versus ≥90), MIB1 (<80 versus ≥80), COO determined by gene expression profiling (GEP) (GCB versus ABC versus Type III/unclassified).

The CNS-IPI was then applied to our cohort to investigate the incidence of CNS relapse according to CNS-IPI risk group.

Results:

Key baseline characteristics for the entire trial cohort are shown in Table 1.

CRFs outlining CNS prophylaxis details administered on study were returned in 984/1080 (91.1%) cases, with data missing for 96 cases. A total of 177/984 patients (18.0%) received CNS prophylaxis within the trial. The type of prophylaxis administered was IT-MTX (163/177), IV-MTX (2/177), IT MTX and IT cytarabine (1/177) and prophylaxis type unknown (11/177). Table 2 shows the proportion of patients receiving CNS prophylaxis by EN sites of DLBCL involvement at baseline.
Twenty-three potential cases of CNS relapse were identified. Of these, 2 were excluded following discussion with the local investigator due to (1) presence of a spinal mass which did not penetrate the dura mater and (2) CNS relapse occurred subsequent to initial disease progression. At a median follow-up of 6.5 years, the number of confirmed cases of CNS relapse was 21/1080 (1.9%), including one patient from the PMBL cohort. Over half the events were isolated (n=11), with the remainder occurring in association with recurrence of systemic disease (n=10); and the majority (14/21) occurred in the first-year following study registration. The incidence of CNS relapse was 2.0% (16/807) if prophylaxis was not administered and 2.8% (5/177) for those who received prophylaxis, or 2.5% (4/163) for patients who received IT-MTX.

Baseline characteristics for patients with CNS relapse are shown in Tables 1 and Supplementary Table 1. Data on molecular subtyping (Illumina DASL® platform) was available for 4/21 patients classified as GCB n=2, ABC n=1 and type III/unclassifiable n=1 subtypes accordingly. CNS relapse predominantly involved the brain parenchyma (17/21, 81.0%), for 14/17 this was the only site of CNS relapse, 2/17 had concurrent spinal cord involvement and 1/17 had concurrent leptomeningeal infiltration. Three patients (3/21, 14.3%) had isolated leptomeningeal involvement and for 1 patient (1/21) had a CNS relapse diagnosed on clinical grounds following presentation with a facial nerve palsy and arm weakness in association with increased protein in the cerebrospinal fluid (CSF).

The median time to progression for a CNS and systemic relapse was 8.1 months (95% CI: 1.0-15.1), and 10.9 months (95% CI: 9.2-12.6) respectively. OS from study registration comparing relapse-free versus systemic relapse versus CNS relapse patient groups is shown in Figure 1. The median OS following a diagnosis of CNS relapse was 3.5 months (95% CI: 0.1–6.9) and 7.7 months (95% CI: 6.0–9.4) following a systemic relapse.

Significant risk factors for CNS relapse by UVA were: WHO PS 2 (p=0.001), elevated LDH (p=0.042), IPI (p=0.004), >1 EN site of disease (p<0.001) and presence of a ‘high-risk’ EN site (p=0.001) (Supplementary Table 2). No factor remained independently significant in MVA based on these 21 cases.

Applying the CNS-IPI patients were categorised as low-risk=313/1080 (29.0%), intermediate-risk 563/1080 (52.1%) and high-risk=204/1080 (18.9%) accordingly. The proportion receiving CNS prophylaxis was 15.3%, 14.4% and 31.4% in each group respectively. The number of CNS relapses by group were: low-risk=2,
intermediate-risk=8 and high-risk=11; with a 2-year [0%, 1.2% (95% CI 0.2- 2.2%) and 5.2% (95% CI 1.9-8.5%)]; and 5-year [0.8% (95% CI 0-2.0%), 1.7% (95% CI 0.5- 2.9%) and 6.8% (95% CI 2.9-10.7%) incidence of CNS relapse accordingly (Figure 2). Adjusting for CNS-IPI risk group according to use of CNS prophylaxis did not demonstrate a clinical benefit [HR=1.12 (95% CI: 0.40-3.14, p=0.83)] (Supplementary Table 3).

**Discussion:**

At a median follow-up of 6.5 years the cumulative incidence of CNS relapse of 1.9% following R-CHOP was very low. The majority of relapses involved the brain parenchyma and isolated leptomeningeal involvement was rare. Relapses in the CNS tended to occur earlier than systemic relapse, and most (14/21) occurred within the first year following registration. Consistent with prior studies[1] the prognosis following CNS relapse in our cohort was poor, with a median OS of 3.5 months. One patient with CNS relapse was from the recently reported PMBL subgroup analysis equating to an incidence of CNS relapse for this cohort of 2.0% (1/50), consistent with published reports in the rituximab era.[20] Although several risk factors for CNS relapse were identified on UVA, none remained independently significant in MVA due to the low number of events. None of the biomarkers tested were significant in UVA, but this must be interpreted in the context of low numbers tested. Application of the CNS-IPI identified a high-risk group with 2 and 5-year incidences of CNS relapse of 5.2% and 6.8% respectively, providing further validation for this risk model. The incidence of CNS relapse for patients selected to receive prophylaxis was 2.8% (2.5% for patients who received IT-MTX) which might suggest some efficacy for this therapy; however when we evaluated the CNS-IPI adjusting for prophylaxis use, no benefit could be demonstrated overall, although small numbers in some individual groups limits interpretation. Five patients who developed subsequent CNS recurrence (parenchymal n=4, isolated leptomeningeal n=1) received IT MTX prophylaxis (Supplementary Table 1), highlighting the potential for treatment-failures with this approach.

The strength of our analysis lies in the evaluation of an unselected cohort of DLBCL patients aged ≥18 years who were uniformly R-CHOP-treated within in the setting of a large multicentre prospective clinical trial. The long duration of follow-up is an additional strength given the propensity for late-onset recurrences. However as a retrospective evaluation of a prospective trial, the analysis was not pre-planned and the study was not designed or powered at the outset to evaluate this particular
endpoint. The low number of CNS events also precluded the identification of independent risk factors.

Evaluation of CNS relapse in DLBCL poses several challenges for researchers due to its rarity. Comparison between studies is also inherently difficult due to the heterogeneity of the populations reported in the literature, some of which are selected [4, 6, 10, 12, 13], or include patients with other aggressive B-cell lymphoma histologies as well as DLBCL [4, 16, 21]. Variation in prophylaxis use between cohorts further complicates data interpretation.

The addition of rituximab to CHOP has consistently improved outcomes for patients with previously untreated DLBCL, but the impact on preventing CNS recurrence is more controversial [4–13, 22]. On the whole consensus opinion supports the view that there has been a reduction in CNS relapse in the rituximab era consequent to improved control of systemic disease [2, 3].

The pattern of CNS relapse in DLBCL also appears to have evolved with rituximab, with relapses increasingly involving the brain parenchyma rather than the leptomeninges [1, 7, 8], the latter being more prevalent previously [1]. A higher proportion of CNS recurrences occurring in isolation are also reported for rituximab-treated patients [4, 6] similarly attributed to improved systemic disease control.

Although we also identified a high-risk CNS-IPI group, overall we observed a lower incidence of CNS relapse across all risk groups than that reported by Schmitz et al [16] and the distinction between low and intermediate-risk was less clearly defined in our analysis. This may be explained by differences between the cohorts studied, for example, patients evaluated by the BCCA were older with a higher proportion of patients with increased PS (>2) and IPI, as anticipated with a population-based cohort, in contrast to our trial population where patients with PS >2 were excluded from participation, which may have led to fewer CNS events. Furthermore the indications for CNS prophylaxis differed between studies, in the DSHNHL trials prophylaxis was mandated for patients with involvement of bone marrow, testes or involvement of lymph nodes of the head and neck in 5/8 of these studies [16], while for the BCCA validation cohort prophylaxis was administered to patients with sinus involvement only for the main duration of accrual.

Controversy surrounds CNS prophylaxis given the limited and conflicting evidence-base, potential associated toxicity, and consequent demand placed on hospital services. In practice IT MTX is the most widely used prophylaxis, and while several
studies support this approach[23, 24], not all have demonstrated benefit.[4, 11] Concerns also exist regarding IT administration in terms of preventing parenchymal relapses in particular.[2, 6] As systemic MTX is the mainstay of therapy for primary CNS lymphoma (PCNSL) and given the reported efficacy as CNS prophylaxis [25] many advocate this mode of administration. In our analysis however only a minority of patients (n=2) received IV MTX but despite this, the risk of CNS recurrence was extremely low, even in patients deemed to be high-risk at the outset.

In conclusion, our findings demonstrate a reduction in CNS relapse rates in the rituximab era. For patients selected to receive prophylaxis, the incidence of CNS relapse was 2.8%, which might suggest some benefit, possibly reflected by a low incidence of leptomeningeal relapse (where the IT route of administration is most likely to exert effect); although an exploratory analysis of CNS-IPI group adjusted for prophylaxis use did not show an overall risk reduction. The low number of CNS events we observed overall also calls into question the additional benefit of using IV MTX in this setting, given the potential for increased toxicity. Ultimately randomised clinical trials are required to determine the optimal approach in high-risk patients. In the future incorporation of novel agents such as lenalidomide, ibrutinib, and nivolumab, which are currently being evaluated in combination with R-CHOP, may conceivably reduce CNS relapse rates even further in DLBCL given the emerging data on their efficacy in relapsed or refractory PCNSL in the recently reported clinical studies NCT01956695, NCT02542514 and NCT02857426 respectively.

Acknowledgements

We would like to thank participating centers of the R-CHOP14v21 trial, as well as the patients involved and their families.

Funding

Cancer Research UK provided endorsement and funding of the R-CHOP14v21 trial (CRIKE/03/019). The National Health Service (NHS) provided funding to the National Institute for Health Research (NIHR) Biomedical Research Centres at both University College London and the Royal Marsden Hospital/Institute of Cancer Research, London, UK. Chugai Pharmaceuticals provided an educational grant and lenograstim within the R-CHOP14v21 trial.

Disclosure:
D.C. has received research funding from Amgen, Astra Zeneca, Bayer, Celgene, Medimmune, Merrimack, Merck Serono and Sanofi. E.A.H. has received travel expenses from Takeda and Bristol-Myers Squibb. K.M.A. has received research funding, conference expenses and honoraria for attending or chairing advisory boards from Roche. All other authors declare that they have no conflicts of interest to report.
References:


<table>
<thead>
<tr>
<th></th>
<th>R-CHOP 14 versus 21 cohort</th>
<th>Patients with CNS relapse</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N=1080</td>
<td>N=21</td>
</tr>
<tr>
<td>Median age (range), years</td>
<td>61 (19-88)</td>
<td>59 (38-78)</td>
</tr>
<tr>
<td>Age ≤60 years</td>
<td>476 (44.1%)</td>
<td>11 (52.4%)</td>
</tr>
<tr>
<td>Age &gt;60 years</td>
<td>604 (55.9%)</td>
<td>10 (47.6%)</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>582 (53.9%)</td>
<td>11 (52.4%)</td>
</tr>
<tr>
<td>Female</td>
<td>498 (46.1%)</td>
<td>10 (47.6%)</td>
</tr>
<tr>
<td>Performance status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>544 (50.4%)</td>
<td>9 (42.9%)</td>
</tr>
<tr>
<td>1</td>
<td>392 (36.3%)</td>
<td>4 (19.0%)</td>
</tr>
<tr>
<td>2</td>
<td>144 (13.3%)</td>
<td>8 (38.1%)</td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I (bulky)</td>
<td>79 (7.4%)</td>
<td>1 (4.8%)</td>
</tr>
<tr>
<td>II</td>
<td>323 (30.1%)</td>
<td>3 (14.3%)</td>
</tr>
<tr>
<td>III</td>
<td>317 (29.5%)</td>
<td>4 (19.0%)</td>
</tr>
<tr>
<td>IV</td>
<td>355 (33.1%)</td>
<td>13 (61.9%)</td>
</tr>
<tr>
<td>Bulky disease</td>
<td>533 (49.5%)</td>
<td>12 (57.1%)</td>
</tr>
<tr>
<td>B symptoms</td>
<td>489 (45.3%)</td>
<td>12 (57.1%)</td>
</tr>
<tr>
<td>Elevated LDH</td>
<td>701 (64.9%)</td>
<td>18 (85.7%)</td>
</tr>
<tr>
<td>&gt;1 site of extranodal disease</td>
<td>296 (27.4%)</td>
<td>14 (66.7%)</td>
</tr>
<tr>
<td>IPI score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>83 (7.7%)</td>
<td>1 (4.8%)</td>
</tr>
<tr>
<td>1</td>
<td>233 (21.6%)</td>
<td>1 (4.8%)</td>
</tr>
<tr>
<td>2</td>
<td>306 (28.3%)</td>
<td>3 (14.3%)</td>
</tr>
<tr>
<td>3</td>
<td>279 (25.8%)</td>
<td>6 (28.6%)</td>
</tr>
<tr>
<td>4</td>
<td>154 (14.3%)</td>
<td>9 (42.9%)</td>
</tr>
<tr>
<td>5</td>
<td>25 (2.3%)</td>
<td>1 (4.8%)</td>
</tr>
<tr>
<td>MYC-rearrangement (N=359)</td>
<td>36 (10.0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Double-hit-rearrangement (N=354)</td>
<td>16 (4.5%)</td>
<td>0 (0%)</td>
</tr>
</tbody>
</table>
Table 2: Administration of CNS prophylaxis and incidence of CNS relapse according to sites of DLBCL involvement at baseline

<table>
<thead>
<tr>
<th>Site of lymphoma involvement</th>
<th>N (%)</th>
<th>N (%) with CNS prophylaxis</th>
<th>N (%) with CNS relapse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone marrow*</td>
<td>101 (9.4%)</td>
<td>42 (41.6%)</td>
<td>6 (5.9%)</td>
</tr>
<tr>
<td>Peripheral blood*</td>
<td>0 (0.0%)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Nasal/paranasal sinuses*</td>
<td>6 (0.6%)</td>
<td>6 (100%)</td>
<td>1 (16.7%)</td>
</tr>
<tr>
<td>Orbit*</td>
<td>2 (0.2%)</td>
<td>1 (50.0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Testis*</td>
<td>14 (1.3%)</td>
<td>10 (71.4%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Bone</td>
<td>63 (5.8%)</td>
<td>29 (46.0%)</td>
<td>3 (4.8%)</td>
</tr>
<tr>
<td>Breast</td>
<td>17 (1.6%)</td>
<td>5 (29.4%)</td>
<td>2 (11.8%)</td>
</tr>
<tr>
<td>Epidural space</td>
<td>0 (0.0%)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Kidney and/or adrenal gland</td>
<td>69 (6.4%)</td>
<td>19 (27.5%)</td>
<td>4 (5.8%)</td>
</tr>
</tbody>
</table>

*Administration of CNS prophylaxis was at the local investigator’s discretion but recommended if there was involvement of the following sites at baseline as per protocol.
Figure 1: Overall survival from study registration
Figure 2: Application of the CNS-IPI risk model